PLK1 and ovarian carcinoma: In 2008, a phase I clinical trial involving 20 cancer patients (3 with ovarian cancer) evaluated the potential antitumor activity of Rigosertib, the only non-ATP competitor PLK1 inhibitor that is also a known RAS inhibitor and PI3K inhibitor (Iliaki et al., 2021; Jimeno et al., 2008).